IMBRUVICA® is indicated for the treatment of patients with Waldenström’s Macroglobulinemia (WM)

INN:

Subtype:

Waldenström Macroglobulinemia (WM)

License:

FDA

Class:

BTK inhibitor

Newly Diagnosed

PIhttps://www.janssenmd.com/pdf/imbruvica/PI-Imbruvica.pdf 

1. Approved Labelling

IMBRUVICA® is indicated for the treatment of patients with Waldenström’s Macroglobulinemia (WM) 

2. Treatment Regimen 

The recommended dose of Imbruvica for WM is 420 mg (three 140 mg capsules) orally once daily until disease progression or unacceptable toxicity.

3. AE/Warnings

Please see section 5 of the PI.

All content on this site is intended for healthcare professionals only. If you are a patient or carer, please visit the Lymphoma Coalition.